BioCryst Pharmaceuticals (NASDAQ:BCRX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a report released on Tuesday morning, Benzinga reports. They currently have a $30.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ Q2 2024 earnings at ($0.14) EPS, Q3 2024 earnings at ($0.10) EPS, Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.51) EPS, FY2025 earnings at ($0.08) EPS, FY2026 earnings at $0.43 EPS and FY2028 earnings at $1.31 EPS.

Separately, Needham & Company LLC reiterated a buy rating and issued a $12.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, April 10th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of Moderate Buy and a consensus target price of $14.00.

BioCryst Pharmaceuticals Stock Up 4.7 %

BioCryst Pharmaceuticals stock opened at $5.34 on Tuesday. The company’s 50-day moving average price is $4.89 and its two-hundred day moving average price is $5.45. The stock has a market cap of $1.10 billion, a P/E ratio of -4.99 and a beta of 1.96. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $8.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The firm had revenue of $92.80 million during the quarter, compared to analyst estimates of $85.62 million. During the same period in the prior year, the company earned ($0.28) earnings per share. The business’s quarterly revenue was up 34.9% compared to the same quarter last year. Equities analysts anticipate that BioCryst Pharmaceuticals will post -0.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Braidwell LP raised its stake in BioCryst Pharmaceuticals by 92.1% during the third quarter. Braidwell LP now owns 5,362,980 shares of the biotechnology company’s stock worth $37,970,000 after acquiring an additional 2,571,100 shares in the last quarter. Vanguard Group Inc. lifted its stake in BioCryst Pharmaceuticals by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 15,392,319 shares of the biotechnology company’s stock valued at $108,978,000 after purchasing an additional 302,270 shares during the last quarter. Jump Financial LLC boosted its position in BioCryst Pharmaceuticals by 371.5% in the third quarter. Jump Financial LLC now owns 404,913 shares of the biotechnology company’s stock valued at $2,867,000 after buying an additional 319,037 shares in the last quarter. Deerfield Management Company L.P. Series C grew its stake in shares of BioCryst Pharmaceuticals by 148.6% during the third quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company’s stock worth $23,265,000 after buying an additional 1,964,000 shares during the last quarter. Finally, Rice Hall James & Associates LLC increased its holdings in shares of BioCryst Pharmaceuticals by 21.5% during the third quarter. Rice Hall James & Associates LLC now owns 2,275,638 shares of the biotechnology company’s stock worth $16,112,000 after buying an additional 402,674 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.